Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...
Next up for Adaptimmune is a filing next year for a second T-cell therapy, NY-ESO-1-targetting letetresgene autoleucel or lete-cel, for synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback